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Abstract
Background: Controlled clinical trials produced contradictory results with respect to a specific
analgesic effect of acupuncture. There is a lack of large multi-centre acupuncture trials. The German
Acupuncture Trial represents the largest multi-centre study of acupuncture in the treatment of
chronic pain caused by gonarthrosis up to now.
Methods: 900 patients will be randomised to three treatment arms. One group receives verum
acupuncture, the second sham acupuncture, and the third conservative standard therapy. The trial
protocol is described with eligibility criteria, detailed information on the treatment definition,
blinding, endpoints, safety evaluation, statistical methods, sample size determination, monitoring,
legal aspects, and the current status of the trial.
Discussion: A critical discussion is given regarding the considerations about standardisation of the
acupuncture treatment, the choice of the control group, and the blinding of patients and observers.
Background
Acupuncture is a traditional Chinese method of medical
treatment that uses thin needles to stimulate specific
points of the body. Throughout the seventies acupuncture
was scientifically studied in many experimental clinical
studies. However, controlled clinical trials produced con-
tradictory results with respect to a specific analgesic effect
of acupuncture compared to placebos. Based on this expe-
rience, a NIH-Consensus-Conference on acupuncture [1]
recommended the initiation of further methodologically
well designed clinical trials to investigate the therapeutic
effects of acupuncture.
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In Germany the reimbursement of an acupuncture-treat-
ment has been restricted by decision of the Federal Com-
mittee of Physicians and Health Insurance Funds, dating
from October 16, 2000. Now, reimbursements of acu-
puncture are only given for the indications migraine,
chronic tension headache, chronic unspecific low back
pain, cox- and gonarthrosis when treated within the
framework of a so-called model project. It is intended,
that the decision for reimbursement of acupuncture will
be based on the results of model projects.
The federal association of the AOK and other German
health insurance associations agreed to perform such a
model project in co-operation with the University of
Bochum on a scientific basis to study the quality of health
care given by acupuncture treatment. The Universities of
Heidelberg, Marburg and Mainz joined this agreement to
build four regional trial groups that perform four different
randomised clinical trials.
This model project is named German Acupuncture Trials
(GERAC) and contains a cohort-study and four ran-
domised controlled trials [2]. The cohort-study collects
data on a patient's self-assessment and the physician's
assessment of the effect of an acupuncture treatment.
Safety aspects are of special interest. Imbedded in the
model project are four randomised controlled trials to
compare verum acupuncture, sham acupuncture and a
standard therapy with respect to efficacy and safety in four
relevant indications. These indications are chronic ten-
sion headache, migraine, chronic unspecific low back
pain [3] and gonarthrosis.
We present the trial protocol of the GERAC-gonarthrosis
study with regard to the specific challenges in acupuncture
trials. In detail we describe our considerations on the
standardisation of the acupuncture treatment, the choice
of the control group, and the blinding of patients and
observers.
Methods
The presented study is a multi-centre, randomised, con-
trolled, 3-armed clinical trial conceived as parallel-group
design with blinded observation of the primary endpoint
via telephone interview. The trial was designed by a steer-
ing committee. External information from a scientific
advisory board and several clinicians was used to define
the acupuncture treatment. The goal of the trial is an
assessment of the efficacy with respect to pain and func-
tionality, the patient's condition and safety of a standard-
ised acupuncture in the treatment of chronic pain caused
by gonarthrosis in comparison to sham acupuncture and
to a conservative standard therapy. Sham acupuncture
means needling the patient at defined non-acupuncture
points. In this trial we are interested in the specific effect
of needling acupuncture points. Many previous trials
using sham acupuncture may have failed because of the
difference in the treatment effect might have been too low
for the chosen small sample size. Therefore in our study it
is planned that about 300 clinical practices include a total
of 900 patients, 300 patients for each treatment arm. The
investigator of each clinical site must have at least training
in acupuncture of 140 hours (A-Diploma) and two years
experience in acupuncture. The inclusion and exclusion
criteria of the patients are described in table 1.
Interventions
A standard for verum acupuncture was defined to treat
gonarthrosis. This treatment is based on recommenda-
tions for an optimised acupuncture treatment in clinical
studies [4] and based on the most distinguished German
textbooks [5-10], as well as from International Studies
[11-14]. Furthermore, the therapy was discussed with
experts in the field of acupuncture.
The most important and most cited local points in litera-
ture were chosen as obligatory points. Therefore the fol-
lowing local points have to be used for every treatment on
the affected knee: ST 34, ST 36, Xiyan (Extra 32,
including2 needles), SP 9, SP 10 and GB 34. Points of this
combination can be omitted only in exceptional cases
with documentation, e.g. needling was not tolerated,
inflammation or skin injury covering the acupuncture
point. In every treatment, the knee and adjoining muscu-
lature are examined for further, pressure-sensitive points
(Ahshi Points). In addition to the obligatory points, one
to four of these Ahshi points per knee may also be treated
with acupuncture. These Ahshi points may be equivalent
to the following local acupoints: LR 7, LR 8, KI 10, BL 40,
GB 33.
A selection of the most important distant points to treat
pain in the knee is provided, of which up to two distant
points (maximum of four needles) can be chosen for an
appropriate therapy in accordance to the individual Chi-
nese syndrome-based diagnosis and the localisation of the
cardinal symptom. The use of distant points is not essen-
tial. Only the following distant points may be used: LI 4,
LI 10, LR 3, ST 44, ST 40, BL 23, BL 60, SP 5, SP 6, KI 3, KI
7, LI 15, SI 10, SI 8, TE 14, LU 6. The choice of distant
points should be selected prior to the first acupuncture
session. This selection can be changed before starting a
new acupuncture session if needed.
Therefore the minimum number of needles is 7 and the
maximum is 15. Treatment is performed with sterilised
disposable steel needles, 30 × 0.3 mm. The depth of nee-
dling should be about 0.5 – 3.5 cm according to the local-
isation of points [9]. After needle insertion a DEQI has to
be tried to trigger in the verum group, followed by a man-BMC Complementary and Alternative Medicine 2004, 4 http://www.biomedcentral.com/1472-6882/4/6
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ual stimulation of the needle, which has to be repeated
twice. If both knees are affected, both has to be treated
with acupuncture as indicated.
The treatment with sham acupuncture was standardised
too. To trigger only a minimal unspecific physiological
stimulus, sham acupuncture is applied with a minimal
depth of needling (not exceeding 5 mm), avoiding real
acupoints. A manual stimulation of needles is not
allowed. General procedure, anamnesis, diagnostics and
communication with patients must be performed exactly
as in the verum acupuncture group.
As sham-points ten points in total are chosen, four on
each leg and one on each arm. In localising the points, the
Chinese measure cun is applied: 1 cun corresponds to the
width of a patient's thumb.
• One point between the gall bladder- and stomach-
meridian on the distal part of the fibula, 2 cun above the
Malleolus lateralis, in the direction towards the knee.
• At each case, one point 2 cun and 6 cun above the Malle-
olus medialis in the center of the tibia surface area intrac-
utaneous without periost contact, in the direction towards
the knee.
• One point in the centre of the thigh on the connecting
line from the centre of the patella to spina iliaca anterior
superior, in the direction towards the hip.
• One point on the highest spot of the tightened musculus
biceps brachii.
Patients randomised to one of the two acupuncture arms
get 10 acupuncture treatments within the first six weeks
with a duration of needling of 20–30 minutes. Patients in
the conservative standard therapy arm should have also
10 visits to try to have the same devotion. Patients graded
as "partially successfully treated" during the interview in
week 7 are allowed to receive five additional visits/treat-
ments. The criteria is based on a global pain score and not
known to the investigator.
Table 1: Eligibility criteria
Inclusion criteria
Age above 40 years
Member of a Health Insurance Company that participates in the "Model Project"
Signed informed consent
Chronic pain in at least one knee joint during the last six months as minimum according to the ACR-criteria [26]
Radiological signs of a gonarthrosis in the same knee (Kellgren 2 or 3) [27]
WOMAC ≥ 3 points (on a scale of 0–10)
Von Korff Chronic Pain Score ≥ 1
Exclusion criteria
A systemic disease of the musculosceletal system
Bone tumour, bone tumour like lesions or metastasis
Bone fracture in the lower extremities during the last three months
Acute infection or osteonecrosis in the knee joint
Surgery of the afflicted extremity during the last six months or planned surgery
Radiological signs of a severe gonarthrosis of a Kellgren grade 4
Other pain conditions which compels the patient to take analgesics for more than three days during the last four weeks
Addiction to analgesics, opiate or other drugs
Acupuncture treatment in the past 12 months
Acupuncture treatment of gonarthrosis.
Ongoing cortico-steroid therapy or cortisone injections in the past six weeks
Dermatological disease within the acupuncture area impairing acupuncture treatment
Medical diseases causing an impairment of physical capacity (NYHA > II)
Severe Coagulopathy
Ischialgia or other neurological diseases
History of epilepsy and psychiatric diseases
Pregnant or breast-feeding patients
Inability to follow instructions (insufficient command of language, dementia)
Participation in another clinical study
Ongoing legal proceedings concerning pension entitlementBMC Complementary and Alternative Medicine 2004, 4 http://www.biomedcentral.com/1472-6882/4/6
Page 4 of 7
(page number not for citation purposes)
All patients treated with acupuncture or sham acupunc-
ture are allowed during the first two weeks of treatment to
take Diclofenac (up to 150 mg/day) or Rofecoxib (up to
25 mg/day). During the third treatment week until the
end of week 23 of the trial the patient is allowed to use a
total dose of 1.000 mg Diclofenac (max. dose 150 mg/
day) or a total dose of 175 mg Rofecoxib (max. dose 25
mg/day). During the last three study weeks before meas-
urement of the primary endpoints of the study no further
pain medication is allowed. In case of emergency the use
of up to 150 mg/day Diclofenac is allowed during the
whole duration of the trial, but has to be counted as treat-
ment failure.
The conservative standard therapy includes medication up to
150 mg/day Diclofenac or 25 mg/day Rofecoxib accord-
ing to the need of the patient. The duration of the medical
treatment is not restricted, but counted as treatment fail-
ure if medication is needed in the last three weeks before
measurement of the primary endpoint in week 26.
Each of the three treatment arms are completed by physi-
cal therapy (six physical therapy sessions, e.g. isometric
training of muscles, walking school, exercises with medi-
cal equipment).
All patients may receive orthopaedic modification of
shoes and in case of gastrointestinal risk Omeprazol (20
mg/day) or Misoprostol (4 × 200 mg/day). For all patients
explicitly excluded during the time of trial are intake of
cortico-steroids, non-narcotic analgetics except
Diclofenac and Rofecoxib. Also not allowed are injections
of any kind, moxibustion, cupping and electro
acupuncture.
Blinding and randomisation
The patients can only be blinded with respect to the acu-
puncture treatment given. Blinding with respect to the
standard therapy is not possible. The investigator cannot
be blinded. The WOMAC, the global patient assessment,
and the SF12 are measured during a telephone interview
performed by a call centre. The person performing the
interview is blinded with respect to the therapy of the
patient. Patients blindness to the mode of acupuncture is
assessed after the last follow up by asking the patient to
guess their group assignment. Additionally, patients are
asked directly after the intervention phase for the quantity
of care they have received during the treatments.
The 1:1:1 block-randomisation, stratified by the trial cen-
tre, is performed from an independent centre via fax.
Endpoints
The primary endpoint is a success rate using a validated
German version of the Western Ontario and McMaster Uni-
versity Osteoarthritis index (WOMAC) [15,16]. The
WOMAC-score (0–100) consists of 24 questions, five of
them being related to pain intensity, two to stiffness of the
knee and 17 to the functionality of a knee joint. The suc-
cess is defined as an improvement of at least 36% com-
pared to the baseline measurement before treatment [17]
26 weeks after starting the treatment. If only one knee of
the patient is afflicted, the assessment of the WOMAC
relates to this knee. If the patient has two afflicted knees,
of which only one meets the ACR-criterion and Kellgren 2
or 3, only this knee is considered. In case that both knees
are afflicted in accordance to inclusion criteria (ACR and
Kellgren 2 or 3), one knee is randomly chosen for the
score.
Secondary endpoints: The success rate based on changes
of the WOMAC from baseline to week 13; the absolute
changes in the WOMAC-score between baseline measure-
ments and measurements taken in week 13 or 26; the suc-
cess rate based on the global patient assessment in the weeks
7, 13 and 26 (success is defined by rating of 1, 2 or 3 on a
6-point scale); the changes in the eight profiles of the SF
12  and the relevant summary scores between baseline
measurement and the measurements taken in the week 13
and 26; the changes in the von Korff Chronic Pain Score
[18]. The von Korff Chronic Pain Score will be used to
compare pain levels of the four different RCTs of GERAC.
Further secondary outcome criteria were number of days
unable to work, amount of analgesics taken by the
patients, number of adverse and severe adverse events.
All efficacy parameter are taken during telephone inter-
views performed by a call centre (Table 2).
Safety evaluation
In each visit, the investigator has to ask a patient if he or
she has suffered adverse events since the last visit. Analysis
of safety data is performed with respect to frequency of
adverse events as a whole, of adverse events in the three
different therapy groups, of adverse events stratified with
respect to severity, of serious adverse events, of adverse
Table 2: Time schedule for each patient
Week Action
-2 Screening
-1 Telephone interview, baseline
0 Randomization
0–6 Treatment
7 Telephone interview, endpoints
7–13 Where applicable: treatment prolongation
13 Telephone interview, endpoints
26 Follow-up visit and telephone interview, endpointsBMC Complementary and Alternative Medicine 2004, 4 http://www.biomedcentral.com/1472-6882/4/6
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events stratified by aetiology, and of adverse events strati-
fied by system organ classes (MedDRA).
Statistical analyses
Statistical methods are used to assess the quality of data,
homogeneity of treatment groups and the assessment of
efficacy and safety of treatments given. The analysis is per-
formed on the basis of an intention to treat (ITT)
population and with respect to ITT principles. A patient
belongs to the ITT population if at least one treatment has
been carried out after the randomisation and the patient
participated on at least one treatment session. The pri-
mary endpoint will also be analysed on the basis of a "per
protocol" population.
To compare the three treatment arms multiple testing is
performed according to the closed test procedure. First the
global test of WOMAC-criteria will be performed. If the
global test of WOMAC-criteria is non-significant then no
further testing will be performed. If it is significant, all
two-group comparisons will be tested. This procedure
guarantees the overall alpha error of 5% even if all single
statistical tests are performed on the 5%-level.
As a statistical model a logistic regression on individual
(not marginal) changes is used to interpret the individual
odds ratios (likelihood-ratio test). The model incorpo-
rates centre and number of treated knee joints as stratifi-
cation variables. In cases of low rates of recruiting in
individual centres, the patients will be combined into
larger units using a nearest-neighbourhood procedure.
In case of the necessity for an interpretation of results in
the sense of a non-inferiority, a confidence interval
approach will be used. As the non-inferiority margin for
the odds ratio 0.4 will be used, derived with parametric
bootstrap based on 8 points as non-inferiority margin on
the WOMAC (0–100) scale [19].
The statistical analyses of the secondary endpoints have
explorative character. A univariate analysis with respect to
the different treatments will be performed for the dichot-
omised as well as an ordinal WOMAC-measurement in
week 6, 13 and 26. Both dimensions calculated from the
SF12 measurements will be presented graphically for
every treatment group in week 6, 13 and 26. This allows a
comparison between the treatment groups but also the
observation how the health status may change in the
course of time. The global patient assessment will be ana-
lysed as ordinal as well as dichotomised (1–3 defined as
success) variable.
Sample size
In sample size calculation, we slightly modified the
approach of Farrar [20] regarding the effect of the verum
acupuncture. For the primary endpoint, the following
assumptions are made: Success rate standard therapy
40%, sham acupuncture 50%, verum acupuncture 60%,
30% dropout (a dropout is counted as failure). This mod-
ifies the success rates to 28%, 35%, 42%. To detect a sig-
nificant difference on a global alpha error of 5% with a
power of 90% between these three groups of therapy, 294
patients per group are required for this scenario (nQuery
Advisor V 1.0, based on Formula 5 from [21]).
The confirmative analysis uses a logistic regression with
likelihood-ratio test instead of a Chi2-test. Via simulation
it can be shown that the power of the likelihood-ratio test
is 91%. Also the use of covariates means a slight gain of
power [22].
Monitoring
The aims of the monitoring consist of making sure that
the rights and the welfare of all participants in this study
are ensured in the clinical sites as well as having high qual-
ity data. This is granted by observing the compliance with
the study protocol, the GCP-guidelines and legal regula-
tions by five external monitoring centres. To increase the
compliance with the trial protocol and the quality of data
each investigator had to attend one instruction course
before starting the recruitment of patients. Here detailed
information was given to the trial protocol, the case report
forms and the verum and sham acupuncture technique.
Furthermore, to assure the quality of data, entries in the
CRF are checked according to completeness, correctness
and comprehension during four monitoring visits in each
centre. Queries for discrepancies are generated in Heidel-
berg and must be solved. For all study participants the
examination of basic facts should be completely reported,
i.e. existing patient, patient number and initials, the avail-
ability of written informed consent, serious adverse events
and their correct report. For 10% of the study participants
all entries which are relevant for the efficacy and safety
analysis will be verified completely.
Additionally the monitor observes the progress of recruit-
ing patients in each study centre and if necessary the par-
ticipating physician will be reminded of the study by a
telephone call. Finally each investigator can demand for
the help of a study nurse if there are any problems with
the documentation of the first patients.
Ethical and legal aspects
The study is conducted according to the Declaration of
Helsinki, the Good Clinical Practice (ICH-E6), and the
German laws. Patients are included after information
about the study and signing the informed consent. The
trial protocol was approved by the Independent Ethics
Committee (IEC) of the medical faculty at Heidelberg, as
well as by the IECs responsible for the clinical sites. ABMC Complementary and Alternative Medicine 2004, 4 http://www.biomedcentral.com/1472-6882/4/6
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patient's insurance was effected in order to cover risks
connected directly with the study.
Current status of the trial
Recruitment of patients was started in November 2001.
But it took about one year having a proper recruitment
rate. It is intended to include patients until March 2004.
The follow-up ends in autumn 2004. Currently 300 clini-
cal sites are involved in the study.
Discussion
Publishing information about ongoing trials is quite
uncommon until now. Report of a trial with no results
seemed to make no sense. Why should we provide infor-
mation about ongoing trials? Mainly three issues justify
the publication of protocols:
Detailed information about ongoing trials can give help-
ful information about research activities, treatment defini-
tions, design of the trial, endpoints and statistical
procedures. Beyond new clinical trials also systematic
reviews are of interest. Published methods can reduce
publication bias because publishing results even if they
are negative is obligatory. Additionally the reviewer is able
to look for published protocols and study registers to
investigate the publication bias [23]. Due to the same
intention of registers we added the trial to the current con-
trolled trials register http://www.controlled-trials.com. A
further topic is the quality of analyses and interpretations
of clinical trials. For the interpretation of clinical trial
results it is necessary to know whether the analysis was
planned or only post hoc. A published study protocol can
simply be compared to the results of the trial. Therefore
planned and post hoc analyses are distinguished very care-
fully in the presentation of the results.
GERAC is currently the largest randomised clinical trial in
acupuncture on patients with chronic pain due to gonar-
throsis. We tried to design the trial as good as possible but
all trials, especially acupuncture trials, have their advan-
tages and disadvantages regarding blinding, treatment,
and investigators:
Blinding in acupuncture trials as one method to reduce
bias is difficult. But we include only patients without acu-
puncture experience for gonarthrosis and have blinded
assessment of endpoints. The advantage of the telephone
interview is that the assessor has less influence to answers
of the patients than in an face to face interview. Also the
patient is able to stay in his habitual environment and
may be prepared by receiving the questionnaire before.
The comparator of the verum acupuncture is a sham acu-
puncture and we are aware that each needle stimulation
might have physiological effects and therefore sham acu-
puncture is not a real placebo. We deliberately do not use
the placebo needle which does not penetrate the skin
[24]. Using the placebo needle one is able to detect any
effect of needling. But sham acupuncture as control group
matches with our study aim to investigate whether the
effect depends on the acupuncture points or not.
We are aware that one disadvantage of this study might be
the exclusion of moxibustion and ear acupuncture. But
the aim is to investigate body acupuncture. Furthermore
blinding with moxibustion is not possible. Therefore we
do not know how much this might influence the effect of
acupuncture. However, we investigate a standardised acu-
puncture even if some practitioners will disagree with our
choice of acupoints. But the advantage of standardisation
is to receive reliable results. If negative or positive, they
only count for this special standardised treatment. Fur-
ther, we do not exactly know which is the optimal number
of acupuncture treatments. According to a consensus of
leading acupuncture experts we decided to treat ten times
with the possibility of a further five treatments if the
patient's condition does improve somewhat, but not
sufficiently.
Performing the trial as a multi-centre pragmatic trial on
outpatients seems to provide us with an estimation of
realistic effects. But one criticism might be that too many
treatment sites were included. Too many investigators
might influence the results in different ways. Therefore the
therapy is standardised, all investigators have to have at
least the A-Diploma and 2 years experience of practising
acupuncture, the statistical analysis adjusts for the investi-
gator heterogeneity, and the quality of data is improved
by extensive monitoring and the query process.
Actually there is a second model project (ART = Acupunc-
ture randomised trials) in Germany including also a trial
about acupuncture and gonarthrosis [25]. The design of
GERAC and ART is different, which provides complemen-
tary information. The results of the gonarthrosis trials will
be comparable due to the use of the WOMAC-Score as pri-
mary endpoint. Both trials compare a standardised acu-
puncture treatment with sham acupuncture, but the third
group is different: No further treatment is given in the ART
trial (waiting list) and a medical treatment is given in the
GERAC trial. In the interpretation of the results it has to be
considered that assessment of the primary endpoint in
GERAC is in the 26th week after begin of the treatment,
while in ART it is in the 8th week. GERAC emphasises the
long term effect and therefore included a higher number
of patients. It must be taken into consideration that the
results of each trial are only valid for the specific defined
acupuncture therapy. E.g. the ART trial allows ear acu-
puncture whereas GERAC does not. A positive result for
the acupuncture treatment does not automatically signifyPublish with BioMed Central    and   every 
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the best possible treatment. Another scheme of acupunc-
ture might as well lead to better (or worse) results. A neg-
ative result of this acupuncture treatment does not imply
that there is no other treatment of acupuncture with a bet-
ter effectiveness.
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